--- title: "Omeros (OMER) news: offering, convertible notes and buyback" url: "https://aibio.space/companies/omeros/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "OMER offering, convertible notes and buyback news: Omeros prices $22 million registered direct offering at $4.10 a share." --- OMER Omeros Corporation NASDAQ · United States # Omeros (OMER) news OMER offering, convertible notes and buyback news Debt Financing · 2026-07-02 ## [Omeros expects to close $16.0 million note repurchase, agrees to $14.5 million more](https://aibio.space/news/omeros-expects-close-16-0-million-note-repurchase-agrees-14-5-million/) Omeros expects to close a $16.0 million principal repurchase of its 9.50% convertible notes due 2029, and agreed to buy up to $14.5 million more. The repurchases would leave about $40.3 million of notes outstanding, and the company may replace the cash with debt that is not convertible into equity. ## Latest Omeros news 1. 2026-06-17 Debt Financing [Omeros agrees to repurchase up to $16.0 million of convertible notes](https://aibio.space/news/omeros-agrees-repurchase-up-16-0-million-convertible-notes/) Omeros agreed to repurchase up to about $16.0 million of 9.50% convertible notes due 2029 for a total of up to about $34.0 million. The final price depends on the stock's trading in an averaging period that began June 18, 2026. 2. 2025-12-01 Mergers [Omeros closes zaltenibart sale to Novo Nordisk, receives $240.0 million and repays term loan](https://aibio.space/news/omeros-closes-zaltenibart-sale-novo-nordisk-receives-240-0-million/) Omeros got $240.0 million upfront and may earn up to $510 million in development and approval milestones and $1.3 billion in sales milestones. About $72.6 million retired its credit agreement and the board approved a buyback of up to $100.0 million. 3. 2025-07-25 Financings [Omeros prices $22 million registered direct offering at $4.10 a share](https://aibio.space/news/omeros-prices-22-million-registered-direct-offering-4-10-share/) Polar Asset Management Partners is buying 5,365,853 shares at a premium of approximately 14% to the closing price on the agreement date. Closing was expected on or about July 28, 2025. 4. 2025-05-15 Debt Financing [Omeros exchanges $70.8 million of 2026 convertible notes for 9.50% notes due 2029](https://aibio.space/news/omeros-exchanges-70-8-million-2026-convertible-notes-9-50-percent/) The one-for-one exchange also means Omeros no longer has to make a $20.0 million term loan prepayment. Separately, it agreed to convert $10 million of the old notes into common stock. ## Omeros at a glance - **Ticker**: OMER - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $132.0 million ### Related companies - [Maze Therapeutics](https://aibio.space/companies/maze-therapeutics/) NASDAQ: MAZE - [MediciNova](https://aibio.space/companies/medicinova/) NASDAQ: MNOV - [Pelthos Therapeutics](https://aibio.space/companies/pelthos-therapeutics/) AMEX: PTHS - [Cellectar Biosciences](https://aibio.space/companies/cellectar-biosciences/) NASDAQ: CLRB - [MacroGenics](https://aibio.space/companies/macrogenics/) NASDAQ: MGNX - [Achieve Life Sciences](https://aibio.space/companies/achieve-life-sciences/) NASDAQ: ACHV - [Shuttle Pharmaceuticals Holdings](https://aibio.space/companies/shuttle-pharmaceuticals/) NASDAQ: SHPH - [Veradermics](https://aibio.space/companies/veradermics/) NYSE: MANE ### Also on NASDAQ - [PMGC Holdings](https://aibio.space/companies/pmgc/) ELAB - [Q/C Technologies](https://aibio.space/companies/q-c-technologies/) QCLS - [aTyr Pharma](https://aibio.space/companies/atyr-pharma/) ATYR - [Curis](https://aibio.space/companies/curis/) CRIS - [Lipocine](https://aibio.space/companies/lipocine/) LPCN - [ASP Isotopes](https://aibio.space/companies/asp-isotopes/) ASPI ## What Omeros does Omeros Corporation is a commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its commercial product, YARTEMLEA (narsoplimab-wuug), is a MASP-2 inhibitor that the company describes as the first and only approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. The FDA approved YARTEMLEA on December 23, 2025, and commercial distribution began in January 2026. A marketing authorization application for TA-TMA is under review by the European Medicines Agency. In November 2025 Omeros completed a transaction under which Novo Nordisk Healthcare AG received exclusive global rights to zaltenibart (formerly OMS906), a late-stage humanized monoclonal antibody targeting MASP-3, for an upfront cash payment of $240.0 million. Omeros retains its MASP-3 small-molecule program. Its clinical pipeline also includes OMS1029, a long-acting lectin pathway antibody, and an OMS527 PDE7 program in cocaine use disorder that is pending initiation of a Phase 1b trial funded by the National Institute on Drug Abuse. Preclinical programs include MASP-2 and MASP-3 small molecules and OncotoX-AML for acute myeloid leukemia. | Product or program | What it is | Stage | |---|---|---| | YARTEMLEA (narsoplimab-wuug) | MASP-2 inhibitor for hematopoietic stem cell transplant-associated thrombotic microangiopathy | Approved in the US; MAA under EMA review | | Zaltenibart (OMS906) | Humanized monoclonal antibody targeting MASP-3, licensed to Novo Nordisk | Late-stage clinical | | OMS1029 | Long-acting second-generation antibody targeting lectin pathway disorders | Phase 1 studies completed | | OMS527 | PDE7 program for cocaine use disorder and other addictive and compulsive disorders | Phase 1b, contracted and pending initiation | | OncotoX-AML | Preclinical program for acute myeloid leukemia | Preclinical | Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/omer20251231_10k.htm). ## Omeros annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$81.3 million](https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/) | [$119.5 million](https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/) | | Net income (loss) | [-$3.4 million](https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/) | [-$156.8 million](https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/) | | Cash from operations | [-$116.1 million](https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/) | [-$148.8 million](https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/) | | Cash and equivalents | [$9.7 million](https://www.sec.gov/Archives/edgar/data/1285819/000143774926027318/) | [$3.4 million](https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/) | | Short-term investments | [$162.1 million](https://www.sec.gov/Archives/edgar/data/1285819/000143774926027318/) | [$86.7 million](https://www.sec.gov/Archives/edgar/data/1285819/000143774926010636/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $2.0 million, plus short-term investments of $130.0 million, $132.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Omeros Has Omeros raised money recently? Our latest story on this, dated Jul 25, 2025: "Omeros prices $22 million registered direct offering at $4.10 a share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/omeros-prices-22-million-registered-direct-offering-4-10-share/). Has Omeros sold convertible notes? Our latest story on this, dated Jul 2, 2026: "Omeros expects to close $16.0 million note repurchase, agrees to $14.5 million more". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/omeros-expects-close-16-0-million-note-repurchase-agrees-14-5-million/). Does Omeros have a share buyback? Our latest story on this, dated Jul 2, 2026: "Omeros expects to close $16.0 million note repurchase, agrees to $14.5 million more". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/omeros-expects-close-16-0-million-note-repurchase-agrees-14-5-million/). What is the ticker symbol of Omeros? Omeros Corporation trades under the ticker OMER on NASDAQ. Where is Omeros listed? Omeros Corporation is listed on NASDAQ. Our directory also records these other listings: GETTEX:3O8; LS:A0NBFF; LSE:0KBU; LSX:A0NBFF. What is the SEC CIK of Omeros? The SEC Central Index Key (CIK) for Omeros Corporation is 1285819. Its filings are on SEC EDGAR. How many shares does Omeros have outstanding? 72,388,316 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Omeros listed under? Our directory records Omeros Corporation under United States. What does Omeros do? Our directory classifies Omeros Corporation as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Omeros? The ISIN recorded for Omeros Corporation is US6821431029. Does aibio.space cover Omeros? aibio.space lists Omeros Corporation among 2,820 public biotech companies and publishes its news here as stories appear. Where is Omeros incorporated? SEC records list its state or country of incorporation as WA. What does Omeros develop? Omeros Corporation is a commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its commercial product, YARTEMLEA (narsoplimab-wuug), is a MASP-2 inhibitor that the company describes as the first and only approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. What is YARTEMLEA (narsoplimab-wuug) from Omeros? YARTEMLEA (narsoplimab-wuug): MASP-2 inhibitor for hematopoietic stem cell transplant-associated thrombotic microangiopathy Stage: Approved in the US; MAA under EMA review. What is Zaltenibart (OMS906) from Omeros? Zaltenibart (OMS906): Humanized monoclonal antibody targeting MASP-3, licensed to Novo Nordisk Stage: Late-stage clinical. ## Investor discussion: Omeros Members talk about Omeros (OMER). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Omeros, newest first. Each line links the filing it comes from. 1. 2026-07-20 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1285819/000143774926023886/omer20260716_8k.htm) 2. 2026-07-06 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1285819/000155278126000377/e26295_omer-8k.htm) 3. 2026-06-18 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1285819/000143774926021040/omer20260618_8k.htm) 4. 2025-12-01 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.02,2.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1285819/000143774925036507/omer20251024_8k.htm) 5. 2025-11-14 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1285819/000155278125000420/e25416_omer-424b5.htm) 6. 2025-07-25 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1285819/000110465925070553/tm2516030-3_424b3.htm) 7. 2025-05-15 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,2.03,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1285819/000143774925017211/ex_799147.htm) 8. 2024-11-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1285819/000143774924034903/omer20240930_10q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:OMER on TradingView](https://www.tradingview.com/symbols/NASDAQ-OMER/). ## SEC filings and registration - **SEC name**: Omeros Corp - **CIK**: 1285819 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: OMER (Nasdaq) - **State or country of incorporation**: WA - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 201 ELLIOTT AVENUE WEST, SEATTLE, WA, 98119 - **Phone**: 206-676-5000 - **Shares outstanding**: 72,388,316 as of 2026-08-07 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1285819/000155278126000441/e26350_omer-8k.htm) filed 2026-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1285819/000143774926027318/omer20260630_10q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1285819/000143774926027313/omer20260521_8k.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1285819/000143774926023886/omer20260716_8k.htm) filed 2026-07-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1285819/000155278126000377/e26295_omer-8k.htm) filed 2026-07-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1285819/000143774926021617/omer20260613_8k.htm) filed 2026-06-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1285819/000143774926021040/omer20260618_8k.htm) filed 2026-06-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1285819/000143774926016720/omer20260331_10q.htm) filed 2026-05-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001285819), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Omeros Corporation is a public biotech or pharmaceutical company listed on NASDAQ under the ticker OMER, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Omeros Corporation - **Ticker**: OMER - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US6821431029 - **Other listed symbols**: GETTEX:3O8; LS:A0NBFF; LSE:0KBU; LSX:A0NBFF - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-OMER/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/omeros/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Omeros (OMER) news: offering, convertible notes and buyback", 2026-10-31, https://aibio.space/companies/omeros/